Effects of estrogen on schizophrenia

Last updated

An increase in symptoms of schizophrenia has been observed to correspond with decreasing levels of estrogen in menopausal women. This observation has led researchers to propose a link between estrogen and schizophrenia. While the first onset of schizophrenia generally occurs between the ages of 20 and 25 for men, first onset occurs approximately 5 years later for women, with a second peak (late onset schizophrenia) between the ages of 40 and 45. Animal studies suggest that estrogen acts as a barrier to dopamine receptors, and so may prevent the increase in dopamine found in patients with schizophrenia. However, in contradictory studies, estrogen either increased or decreased dopamine receptors, depending on the duration of the experiment.

Contents

When estrogen levels are low, women are more susceptible and respond poorly to anti-psychotic drugs. Consequently, estrogen is often used to treat schizophrenia in women. Studies show that estrogen patches can reduce the positive symptoms of schizophrenia (at least in the short term). Researchers believe that estrogen could also be used to treat this disease in men.[ citation needed ]

Age of onset

Gender differences have been observed in the age of onset of schizophrenia. Women have a later age of onset and on average they are diagnosed 2 to 10 years later than men. [1] In fact, the first onset of schizophrenia for men occurs around the ages of 20 to 25, while in women the first onset generally occurs between the ages of 25 and 30 years. [2] However, it has also been noted that in women a second peak in schizophrenia occurs at the ages of 40 to 45. [1] During this period there is a significant drop in estrogen levels in the body. [1] These factors have led researchers to believe that estrogen may have an effect on psychosis in women. [1]

In support of the above-mentioned conclusions many studies have been performed. Doctors Lindamer, Lohr, Harris, and Jeste conducted a study to determine age of onset of schizophrenia in which they examined gender differences in 194 patients ranging in age from 35 to 97. They found that the mean age for onset in men was 30, while in women it was 39. [1] (It is important to note that this is just one study, and overall averages come from a combination of different studies). About 37% of the women developed schizophrenia at the age of 45, while only 16% of men reported the same. [1] Thus, more women than men experience late onset schizophrenia. [1] This indicates that there is indeed another peak for women at the age of 45 and women do develop schizophrenia later in life.

Another study was conducted on older men and women to determine how schizophrenia affects them. The study consisted of 36 women and 86 men, all of similar age. More women than men were found to have paranoid schizophrenia and had more from severe positive symptoms rather than negative symptoms. [1] All of this information is consistent with other studies showing that women have a later age of onset of schizophrenia and have more severe positive symptoms rather than negative symptoms. [1]

Estrogen and dopamine

Genetic factors have much to do with developing schizophrenia. [3] In fact the "heritability of schizophrenia is around 80%, and a first degree relative has a 5 to 10 fold increase in the risk of developing the disorder compared to the risk for the general population." [3] It seems that individuals with schizophrenia inherit problems associated with dopamine in the brain. According to Answers.com, dopamine is a "neurotransmitter... essential to the normal functioning of the central nervous system." [4] In the 1950s Arvid Carlsson "designated the molecule dopamine ... as a neurotransmitter". [5] This led to the dopamine hypothesis of schizophrenia.

Animal studies provide evidence that estrogen regulates dopamine systems. [1] In the studies performed on animals estrogen seems to act as a barrier to dopamine receptors. [1] Thus estrogen may prevent the increase in dopamine found in patients with schizophrenia. This directly supports the idea that estrogen acts as a deterrent. This would explain why women have a peak in the onset of schizophrenia in their late forties since at this time estrogen levels drop in women, causing the dopamine to increase, resulting in psychotic symptoms.

Biochemical studies prove contradictory to this approach. In these studies the estrogen either increased or decreased dopamine receptors, depending on the time allotted for the experiment. [1] This contradicts the theory that estrogen inhibits dopamine receptors, therefore acting as a protectorate against schizophrenia.

Estrogen as a treatment

Estrogen is often used to treat schizophrenia in women. [6] According to an online science article, "Prof. Ina Weiner of Tel Aviv University's Department of Psychology and her doctoral student Michal Arad have reported findings suggesting that restoring normal levels of estrogen may work as a protective agent in menopausal women." [6] This supports the theory that estrogen acts as a protectorate against schizophrenia. According to Dr. Weiner it has been known for a long time that when estrogen levels are low women are more susceptible and respond poorly to anti-psychotic drugs, thus supporting the use of estrogen as a treatment. [6] In the study Dr. Weiner and Arad performed, ovaries were removed from rats resulting in low estrogen much like in menopause. [6] As a result of the ovaries removal the rats showed schizophrenia like symptoms. [6] To test if estrogen replacements work in reducing schizophrenia symptoms the rats were then given estrogen, and as predicted the schizophrenia symptoms decreased. [6] The anti-psychotic drug haloperidol was also given to rats, but showed no signs of relieving the schizophrenia-like behavior, providing evidence for the effectiveness of estrogen in comparison with other anti-psychotic drugs. [6] They also found that estrogen is effective for relieving schizophrenia in both male and female rats. [6] In addition they found that low amounts of estrogen increase the effectiveness of anti-psychotic drugs. [6] Although this study suggests that estrogen helps in alleviating symptoms, many argue that it could have side effects such as cervical cancer and heart attacks. [6]

Vivelle-dot, an estrogen patch Estrogen patch.jpg
Vivelle-dot, an estrogen patch

As a result of her study, Dr. Weiner concluded that women with schizophrenia should be given estrogen supplements in their mid-twenties and in their forties, when estrogen levels are decreased. [6] This would improve the effectiveness of anti-psychotic drugs and would help in assisting women with schizophrenia in maintaining a normal lifestyle without peaks of schizophrenia in their forties. Dr. Weiner also believes that since men are less likely to develop schizophrenia after the age of forty, it is likely that estrogen is the "culprit". [6]

In 2008 a study was done to test the effectiveness of estrogen patches on schizophrenia patients. [7] Over a period of four weeks the individuals tested showed a reduction in positive symptoms; however they showed no differences in negative symptoms. [7] It is still not known exactly how estrogen helps in alleviating schizophrenia, however from this study the researchers felt that perhaps estrogen causes "rapid actions on cerebral blood flow and/or glucose metabolism". [7] They also recognized that receptors for estrogen are located throughout the brain, thus the hormone estrogen can regulate neurotransmitters. [7] They also noted that although in the short term estrogen can have positive effects, they are unsure of its reliability in the long term. [7] However, they stated that they believed that estrogen could also be used in men, as previously found in other studies. [7]

Another study done in 1995 also showed that estrogen relieves positive symptoms in patients. [1] In this study .02 mg of estrogen was administered to premenopausal women with schizophrenia. [1] They found that at first the estrogen increased the efficiency of neuroleptics, but over a long period of time the effect of the estrogen reversed and decreased the efficiency of the drugs. [1] The researchers concluded that while estrogen helps in the short term, in the long term it can be detrimental. [1] These results were also found in the study mentioned previously.

Related Research Articles

Psychosis is a condition of the mind that results in difficulties determining what is real and what is not real. Symptoms may include delusions and hallucinations, among other features. Additional symptoms are incoherent speech and behavior that is inappropriate for a given situation. There may also be sleep problems, social withdrawal, lack of motivation, and difficulties carrying out daily activities. Psychosis can have serious adverse outcomes.

<span class="mw-page-title-main">Psychopharmacology</span> Study of the effects of psychoactive drugs

Psychopharmacology is the scientific study of the effects drugs have on mood, sensation, thinking, behavior, judgment and evaluation, and memory. It is distinguished from neuropsychopharmacology, which emphasizes the correlation between drug-induced changes in the functioning of cells in the nervous system and changes in consciousness and behavior.

<span class="mw-page-title-main">Chlorpromazine</span> Antipsychotic medication

Chlorpromazine (CPZ), marketed under the brand names Thorazine and Largactil among others, is an antipsychotic medication. It is primarily used to treat psychotic disorders such as schizophrenia. Other uses include the treatment of bipolar disorder, severe behavioral problems in children including those with attention deficit hyperactivity disorder, nausea and vomiting, anxiety before surgery, and hiccups that do not improve following other measures. It can be given orally, by intramuscular injection, or intravenously.

<span class="mw-page-title-main">Atypical antipsychotic</span> Class of pharmaceutical drugs

The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), are a group of antipsychotic drugs largely introduced after the 1970s and used to treat psychiatric conditions. Some atypical antipsychotics have received regulatory approval for schizophrenia, bipolar disorder, irritability in autism, and as an adjunct in major depressive disorder.

Hormone therapy or hormonal therapy is the use of hormones in medical treatment. Treatment with hormone antagonists may also be referred to as hormonal therapy or antihormone therapy. The most general classes of hormone therapy are oncologic hormone therapy, hormone replacement therapy, androgen replacement therapy (ART), oral contraceptive pills, and transgender hormone therapy.

The dopamine hypothesis of schizophrenia or the dopamine hypothesis of psychosis is a model that attributes the positive symptoms of schizophrenia to a disturbed and hyperactive dopaminergic signal transduction. The model draws evidence from the observation that a large number of antipsychotics have dopamine-receptor antagonistic effects. The theory, however, does not posit dopamine overabundance as a complete explanation for schizophrenia. Rather, the overactivation of D2 receptors, specifically, is one effect of the global chemical synaptic dysregulation observed in this disorder.

Hot flashes are a form of flushing, often caused by the changing hormone levels that are characteristic of menopause. They are typically experienced as a feeling of intense heat with sweating and rapid heartbeat, and may typically last from two to 30 minutes for each occurrence.

<span class="mw-page-title-main">Raloxifene</span> Chemical compound

Raloxifene, sold under the brand name Evista among others, is a medication used to prevent and treat osteoporosis in postmenopausal women and those on glucocorticoids. For osteoporosis it is less preferred than bisphosphonates. It is also used to reduce the risk of breast cancer in those at high risk. It is taken by mouth.

Latent inhibition (LI) is a technical term in classical conditioning, where a familiar stimulus takes longer to acquire meaning than a new stimulus. The term originated with Lubow and Moore in 1973. The LI effect is latent in that it is not exhibited in the stimulus pre-exposure phase, but rather in the subsequent test phase. "Inhibition", here, simply connotes that the effect is expressed in terms of relatively poor learning. The LI effect is extremely robust, appearing in both invertebrate and mammalian species that have been tested and across many different learning paradigms, thereby suggesting some adaptive advantages, such as protecting the organism from associating irrelevant stimuli with other, more important, events.

<span class="mw-page-title-main">Trace amine</span> Amine receptors in the mammalian brain

Trace amines are an endogenous group of trace amine-associated receptor 1 (TAAR1) agonists – and hence, monoaminergic neuromodulators – that are structurally and metabolically related to classical monoamine neurotransmitters. Compared to the classical monoamines, they are present in trace concentrations. They are distributed heterogeneously throughout the mammalian brain and peripheral nervous tissues and exhibit high rates of metabolism. Although they can be synthesized within parent monoamine neurotransmitter systems, there is evidence that suggests that some of them may comprise their own independent neurotransmitter systems.

<span class="mw-page-title-main">Coumestrol</span> Chemical compound

Coumestrol is a natural organic compound in the class of phytochemicals known as coumestans. Coumestrol was first identified as a compound with estrogenic properties by E. M. Bickoff in ladino clover and alfalfa in 1957. It has garnered research interest because of its estrogenic activity and prevalence in some foods, including soybeans, brussels sprouts, spinach and a variety of legumes. The highest concentrations of coumestrol are found in clover, Kala Chana, and Alfalfa sprouts.

<span class="mw-page-title-main">Clinical neurochemistry</span>

Clinical neurochemistry is the field of neurological biochemistry which relates biochemical phenomena to clinical symptomatic manifestations in humans. While neurochemistry is mostly associated with the effects of neurotransmitters and similarly functioning chemicals on neurons themselves, clinical neurochemistry relates these phenomena to system-wide symptoms. Clinical neurochemistry is related to neurogenesis, neuromodulation, neuroplasticity, neuroendocrinology, and neuroimmunology in the context of associating neurological findings at both lower and higher level organismal functions.

The causes of schizophrenia that underlie the development of schizophrenia, a psychiatric disorder, are complex and not clearly understood. A number of hypotheses including the dopamine hypothesis, and the glutamate hypothesis have been put forward in an attempt to explain the link between altered brain function and the symptoms and development of schizophrenia.

<span class="mw-page-title-main">Animal model of schizophrenia</span>

Research into the mental disorder of schizophrenia, involves multiple animal models as a tool, including in the preclinical stage of drug development.

The epigenetics of schizophrenia is the study of how inherited epigenetic changes are regulated and modified by the environment and external factors and how these changes influence the onset and development of, and vulnerability to, schizophrenia. Epigenetics concerns the heritability of those changes, too. Schizophrenia is a debilitating and often misunderstood disorder that affects up to 1% of the world's population. Although schizophrenia is a heavily studied disorder, it has remained largely impervious to scientific understanding; epigenetics offers a new avenue for research, understanding, and treatment.

Sex differences in schizophrenia are widely reported. Men and women exhibit different rates of incidence and prevalence, age at onset, symptom expression, course of illness, and response to treatment. Reviews of the literature suggest that understanding the implications of sex differences on schizophrenia may help inform individualized treatment and positively affect outcomes.

<span class="mw-page-title-main">Ospemifene</span> Chemical compound

Ospemifene is an oral medication indicated for the treatment of dyspareunia – pain during sexual intercourse – encountered by some women, more often in those who are post-menopausal. Ospemifene is a selective estrogen receptor modulator (SERM) acting similarly to an estrogen on the vaginal epithelium, building vaginal wall thickness which in turn reduces the pain associated with dyspareunia. Dyspareunia is most commonly caused by "vulvar and vaginal atrophy."

Dopamine therapy is the regulation of levels of the neurotransmitter dopamine through the use of either agonists, or antagonists; and has been used in the treatment of disorders characterized by a dopamine imbalance. Dopamine replacement therapy (DRT) is an effective treatment for patients with decreased levels of dopamine. Often dopamine agonists, compounds that activate dopamine receptors in the absence of that receptor's physiological ligand, the neurotransmitter dopamine, are used in this therapy. DRT has been shown to reduce symptoms and increase lifespan for patients with Parkinson's disease. Dopamine regulation plays a critical role in human mental and physical health. The neurons that contain the neurotransmitter are clustered in the midbrain region in an area called the substantia nigra. In Parkinson's patients, the death of dopamine-transmitting neurons in this area leads to abnormal nerve-firing patterns that cause motor problems. Research in patients with schizophrenia indicates abnormalities in dopamine receptor structure and function.

Dopamine supersensitivity psychosis is a hypothesis that attempts to explain the phenomenon in which psychosis occurs despite treatment with escalating doses of antipsychotics. Dopamine supersensitivity may be caused by the dopamine receptor D2 antagonizing effect of antipsychotics, causing a compensatory increase in D2 receptors within the brain that sensitizes neurons to endogenous release of the neurotransmitter dopamine. Because psychosis is thought to be mediated—at least in part—by the activity of dopamine at D2 receptors, the activity of dopamine in the presence of supersensitivity may paradoxically give rise to worsening psychotic symptoms despite antipsychotic treatment at a given dose. This phenomenon may co-occur with tardive dyskinesia, a rare movement disorder that may also be due to dopamine supersensitivity.

Immuno-psychiatry, according to Pariante, is a discipline that studies the connection between the brain and the immune system. It differs from psychoneuroimmunology by postulating that behaviors and emotions are governed by peripheral immune mechanisms. Depression, for instance, is seen as malfunctioning of the immune system.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Lindamer, Laurie A.; Lohr, James B.; Harris, M. Jackuelyn; Jeste, Dilip V. (1 January 2004). "Gender, Estrogen, and Schizophrenia". FOCUS. 2 (1): 138–145. doi:10.1176/foc.2.1.138.
  2. Riecher-Rössler, Anita. "Schizophrenia in Women." Medscape. WebMD, 8 Apr. 2004. Web. 9 Dec. 2010. <http://www.medscape.com/viewarticle/473295>.
  3. 1 2 Nieratschker, Vanessa; Nöthen, Markus M.; Rietschel, Marcella (2010). "New genetic findings in schizophrenia: is there still room for the dopamine hypothesis of schizophrenia?". Frontiers in Behavioral Neuroscience. 4: 23. doi: 10.3389/fnbeh.2010.00023 . PMC   2871716 . PMID   20485477.
  4. "Dopamine." Answers.com. Answers Corporation, 2010. Web. 9 Dec. 2010. <http://www.answers.com/topic/dopamine>.
  5. Qi, Z.; Miller, G.; Voit, E. (May 2010). "Computational Modeling of Synaptic Neurotransmission as a Tool for Assessing Dopamine Hypotheses of Schizophrenia". Pharmacopsychiatry. 43 (S 01): S50–S60. doi:10.1055/s-0030-1248317. PMID   20486051.
  6. 1 2 3 4 5 6 7 8 9 10 11 12 American Friends of Tel Aviv University. "Estrogen in the fight against schizophrenia." ScienceDaily. N.p., 25 Jan. 2010. Web. 9 Dec. 2010. <https://www.sciencedaily.com/releases/2010/01/100120112212.htm>.
  7. 1 2 3 4 5 6 Gever, John. "Estrogen Patch Boosts Schizophrenia Treatment Success." medpage. N.p., 4 Aug. 2008. Web. 9 Dec. 2010. <http://www.medpagetoday.com/Psychiatry/Schizophrenia/10417>.